February 19, 2019
This Valentine’s Day, our client Boustead Securities, LLC, acting as the sole underwriter, completed the initial public offering (the “Offering”) of Soliton, Inc. (the “Company”) a pre-revenue stage medical device company with a proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center. The Company raised approximately $10.4 million in gross proceeds from this initial closing, before deducting underwriting commissions and other offering expenses, by issuing 2,086,391 ordinary shares at a public offering price of $5.00 per share. Soliton has been approved to begin trading its shares on the Nasdaq Capital Market under the symbol ”SOLY” on Tuesday February 19, 2019. The Offering is the first IPO using Tier II of Regulation A to be completed on Nasdaq or NYSE in over one year.
Hunter Taubman Fischer & Li LLC acted as U.S. legal counsel to the underwriter. Schiff Hardin LLP acted as counsel to the Company in connection with the IPO.
Hunter Taubman Fischer & Li, LLC is a boutique law firm specializing in corporate, commercial and securities transactions, cross-border financing, immigration and taxation. Our team of lawyers works together so our clients can benefit from astute business experience and sophisticated legal solutions.